Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut. Show more

Location: 21 Business Park Drive, Branford, CT, 06405, United States | Website: https://azitrainc.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.921M

52 Wk Range

$0.22 - $12.00

Previous Close

$0.23

Open

$0.23

Volume

678,128

Day Range

$0.22 - $0.23

Enterprise Value

1.574M

Cash

3.207M

Avg Qtr Burn

-2.559M

Insider Ownership

9.54%

Institutional Own.

5.43%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ATR-04 Details EGFRi-Associated Rash	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATR12-351 (ATR-12) Details Netherton syndrome	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.